Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all-cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.
Authors
- Saixian Shi
- Jiahao Li (ORCID: https://orcid.org/0000-0002-5967-5518)
- Xiaofeng Li (ORCID: https://orcid.org/0009-0005-3765-0124)
- Ye Chen (ORCID: https://orcid.org/0000-0002-4511-9262)
- Yan Dai (ORCID: https://orcid.org/0000-0003-4056-6204)
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Xichang University (CN)
Publication Details
- Journal
- Journal of Diabetes
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1111/1753-0407.70044
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Southwest Medical University